Xofluza Approval History
Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor for the treatment of influenza (flu) in people 12 years of age and older.
Xofluza is taken as a single dose orally within 48 hours of onset of symptoms.
The approved recommended dosage of Xofluza is based on body weight:
- Single dose of 40 mg for patients 40 kg to < 80 kg
- Single dose of 80 mg for patients ≥ 80 kg
Important Safety Information
Do not take Xofluza if you are allergic to baloxavir marboxil or any of the ingredients in Xofluza.
Before you take Xofluza, tell your healthcare provider about all of your medical conditions, including if you:
- are pregnant or plan to become pregnant. It is not known if Xofluza can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if Xofluza passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Talk to your healthcare provider before you receive a live flu vaccine after taking Xofluza.
Take Xofluza with or without food. Do not take Xofluza with dairy products, calcium-fortified beverages, laxatives, antacids or oral supplements containing iron, zinc, selenium, calcium or magnesium.
The most common side effects are diarrhea, bronchitis, nausea, common cold symptoms (nasopharyngitis) and headache.
Xofluza is not effective in treating infections other than influenza. Other kinds of infections can have symptoms like those of the flu or occur along with the flu and may need different kinds of treatment. Tell your healthcare provider if you feel worse or develop new symptoms during or after treatment with Xofluza or if your flu symptoms do not start to get better.
Development History and FDA Approval Process for Xofluza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.